Who
David I. Malek
Director
Company insider
Files Form 4 as: Director, Braveheart Bio.
In numbers
- Trades disclosed
- 4
- Buys
- 1
- Sells
- 0
- Bought
- $150K
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 1
- First trade
- 5 Aug 2026
- Last trade
- 7 Aug 2026
- Last filed
- 7 Aug 2026
Companies traded
Activity over time
1 Aug – 1 Oct
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 7 Aug 2026filed 7 Aug 2026 | BRVE Braveheart BioBiotechnology | SEC FORM 4 Bought | $75K4,166 at $18.00 | filing |
| 7 Aug 2026filed 7 Aug 2026 | BRVE Braveheart BioBiotechnology | SEC FORM 4 Bought | $75K4,166 at $18.00 | filing |
| 5 Aug 2026filed 7 Aug 2026 | BRVE Braveheart Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 5 Aug 2026filed 7 Aug 2026 | BRVE Braveheart Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
News
Braveheart Bio (NASDAQ:BRVE) Stock Price Down 7.6% – Here's WhyBRVE · dailypolitical.com · 6 Oct 2026
0 headlines in the last 90 days name David I. Malek; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.